You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 3
  • 36 Prognostic value and association with veliparib benefit of modeled CA-125 elimination kinetics (KELIM) in patients with newly diagnosed ovarian cancer: analysis from the VELIA/GOG-3005 study

Article metrics

Article menu

Download PDFPDF

Oral Poster – TAPED
Oral Featured Posters – Pre-Recorded
IGCS20_1102
36 Prognostic value and association with veliparib benefit of modeled CA-125 elimination kinetics (KELIM) in patients with newly diagnosed ovarian cancer: analysis from the VELIA/GOG-3005 study
Free

 

Online download statistics by month:

Online download statistics by month: November 2020 to March 2023

AbstractFullPdf
Nov 20202207
Dec 20203607
Jan 20211202
Feb 2021704
Mar 20212707
Apr 20211406
May 2021404
Jun 2021001
Jul 2021006
Aug 2021007
Sep 2021005
Oct 202110018
Nov 202117018
Dec 202112013
Jan 20221103
Feb 20221501
Mar 2022602
Apr 2022902
May 20222205
Jun 20222207
Jul 20223503
Aug 20222506
Sep 20223608
Oct 202224010
Nov 20221105
Dec 20224106
Jan 20233405
Feb 20233405
Mar 20233707
Total5230180